Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A SINGLE-CENTER, PHASE 1, ORAL ADMINISTRATION, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, SINGLE ASCENDING DOSE STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF CENOBAMATE (YKP3089) IN HEALTHY JAPANESE SUBJECTS

Trial Profile

A SINGLE-CENTER, PHASE 1, ORAL ADMINISTRATION, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, SINGLE ASCENDING DOSE STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF CENOBAMATE (YKP3089) IN HEALTHY JAPANESE SUBJECTS

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2018

At a glance

  • Drugs Cenobamate (Primary)
  • Indications Anxiety disorders; Epilepsy; Neuropathic pain
  • Focus Pharmacokinetics
  • Acronyms YKP3089C031
  • Sponsors SK biopharmaceuticals
  • Most Recent Events

    • 01 Oct 2018 Status changed from recruiting to completed.
    • 15 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top